stockrow
Friday 6 November 2026
Export CVRX’s income statement to Excel — free account
CVRx, Inc.
CVRX Healthcare Medical Devices
CVRx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $56.7 million, up 10.4% from fiscal 2024.
- Revenue
- −5.84%
- EPS
- −6.12%
- Free cash flow
- −9.91%
- Total debt
- +18.6%
Quarter to September 2026, against a year earlier
0.87
0.60
−40.82%
Follow CVRX
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
3.27 | 4.22 | 2.23 | 0.79 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(18.98) | (20.50) | (15.44) | (4.38) | |
P/B ratio |
4.71 | 8.57 | 6.83 | 3.45 | |
Price to Tangible BV |
4.71 | 8.57 | 6.83 | 3.45 | |
EV/Sales |
2.87 | 4.04 | 2.18 | 0.84 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(4.04) | (6.04) | (3.30) | (1.22) | |
EV/FCF |
(3.98) | (5.95) | (3.25) | (1.21) | |
Quick Ratio |
6.49 | 8.58 | 6.65 | 5.46 | |
Current Ratio |
7.63 | 10.20 | 8.04 | 6.80 | |
Net Debt/EBITDA |
2.39 | 1.16 | 0.47 | 0.01 | |
Debt/Assets |
47.25% | 58.65% | 63.47% | 66.95% | |
Debt/Equity |
1.26 | 2.01 | 2.94 | 4.24 | |
Asset Turnover |
0.48 | 0.52 | 0.58 | 0.61 | |
Operating CF/Net income |
0.82 | 0.93 | 0.63 | 0.77 | |
Capex/Depreciation |
(0.28) | (0.42) | (0.38) | (0.34) | |
Interest Coverage |
(7.89) | (7.84) | (8.25) | (8.12) | |
Research and Development Expense of Revenue |
18.72% | 20.88% | 19.93% | 19.19% | |
Selling, General and Administrative Expense of Revenue |
137.35% | 148.68% | 150.38% | 161.86% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
17.43% | 19.74% | 23.34% | 20.76% | |
Graham Net Nets |
0.20 | 0.10 | 0.13 | 0.24 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(28.87%) | (21.35%) | (38.52%) | (114.86%) | |
Free Cash Flow Yield |
(22.00%) | (16.11%) | (30.12%) | (88.18%) | |
Revenue per Share |
0.61 | 0.56 | 0.59 | 0.51 | |
Operating CF per Share |
(0.37) | (0.46) | (0.33) | (0.40) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.38) | (0.47) | (0.34) | (0.40) | |
Cash per Share |
2.90 | 2.74 | 2.44 | 2.16 | |
Shareholders Equity per Share |
1.51 | 1.10 | 0.75 | 0.51 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.51 | 1.10 | 0.75 | 0.51 | |
Free Cash Flow |
(9.83) | (12.29) | (8.94) | (10.99) | |
Working Capital |
88.33 | 87.26 | 78.36 | 72.51 | |
Capital Expenditures |
(0.07) | (0.12) | (0.11) | (0.10) | |
Net Current Asset Value |
36.18 | 26.13 | 17.16 | 11.23 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.01 | 0.01 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
9.97 | 9.06 | 8.28 | 8.90 | |
Average Payables |
3.21 | 2.87 | 3.45 | 3.89 | |
Average Inventory |
12.16 | 12.04 | 12.37 | 12.51 | |
Average Assets |
119.10 | 114.66 | 105.92 | 99.47 | |
Average Common Equity |
55.19 | 49.23 | 38.94 | 30.94 |
Columns are period end dates · fundamentals updated 5 Nov 2026